Blog

Whipple surgery and endoscopic treatment are two different categories of intervention in pancreatic and biliary disease. Whipple is a major open operation that removes the head of the pancreas with curative intent in resectable cancer. Endoscopic treatment is a group of minimally invasive scope-based procedures used for biopsy, biliary drainage, pain management, and palliation. The two aren’t alternatives. They handle different parts of the same pathway. The mistake patients make is treating them as competing options. According to Dr. Vipulroy Rathod,Gastroenterologist in Mumbai, “Patients walk in hoping endoscopy can replace the Whipple. For resectable cancer it can’t. What endoscopy does well is everything around the operation. Biopsy. Drainage. Pain control. Without that work, the Whipple doesn’t go well, and for patients who aren’t surgical candidates, endoscopy is the entire treatment.” Whipple vs endoscopic treatment at a glance Factor Whipple Surgery Endoscopic Treatment Approach Major open surgery Through a scope Intent Curative removal Staging or palliation Recovery Three to four weeks One to two days Anaesthesia General, prolonged Sedation, short Use in cancer Resectable disease only Almost all stages   When Whipple is the right choice? Whipple is considered only when two conditions are met. The tumour can be removed in one piece. The patient is fit enough to recover. Resectable pancreatic head cancer. A tumour confined to the head of the pancreas without major vessel involvement. Removed together with surrounding lymph nodes so the pathologist can stage it properly. Periampullary tumours qualify for the same operation. Cancers of the ampulla of Vater, distal bile duct, and duodenum next to the pancreas. Outcomes are often noticeably better than for pancreatic adenocarcinoma itself. Neuroendocrine tumours and premalignant IPMNs. Selected cases with high-risk features go to Whipple. Less common, but the operation is the same and the indication is clear when histology supports it. After successful neoadjuvant chemotherapy. Borderline resectable cases that converted with chemotherapy are taken to Whipple once restaging confirms the tumour has pulled back from vessels. Where Whipple doesn’t belong matters as much. Pancreatic cancer treatment planning excludes Whipple in locally advanced disease, in metastatic cancer, and in patients whose general condition makes recovery unrealistic. Sending the wrong patient into theatre causes more harm than the cancer would in the same period. Where endoscopic treatment fits? Endoscopy isn’t a competitor to Whipple. It’s the work that surrounds it. Diagnosis, drainage, pain management, complication handling. EUS-guided biopsy. Every reasonable pancreatic cancer plan starts here. Tissue from the tumour with millimetre accuracy. Histology decides the regimen, the timing, and whether surgery is even appropriate. ERCP with biliary stenting handles the jaundice that pancreatic head tumours cause. Often the first procedure done after diagnosis, well before any conversation about Whipple is finalised. ERCP after Whipple. Anastomotic strictures, bile leaks, recurrent stones in the reconstructed plumbing. Problems that would otherwise mean repeat open surgery, fixed through a scope instead. EUS-guided celiac plexus block for pain control in unresectable disease. Durable relief, often months at a time, without escalating opioid doses indefinitely. The two approaches work together in modern pancreatic cancer care, not against each other. Read more on pancreatic cancer detection to see how endoscopy fits into the broader pathway, why it usually comes first, and why so many patients are past the Whipple option by the time they’re diagnosed. Why choose Dr. Vipulroy Rathod for pancreatic disease management? Dr. Vipulroy Rathod has been doing advanced endoscopic work in pancreatic and biliary disease at Fortis Hospital Mulund since the late 1990s, with EUS-guided biopsy, ERCP, celiac plexus block, and the staging assessment that decides whether Whipple is the right next step at all. Volume that few centres in India match. The harder skill in pancreatic disease isn’t doing either procedure well. It’s the sorting. Which patient belongs in which corridor, with which preparation, at which week. Multidisciplinary discussion with surgeons and oncologists is where that gets worked out, not in a single specialist’s clinic in isolation. Book your consultation today with one of India’s most experienced specialists for pancreatic disease assessment and treatment planning. Book Appointment Call now Frequently Asked Questions Can endoscopic treatment replace Whipple surgery? Not for resectable cancer. What is the recovery time after Whipple surgery? Seven to ten days in hospital, three to four weeks at home before normal activity. Full recovery runs two to three months. Is endoscopic treatment safer than Whipple surgery? Safer in immediate complication terms, but the two aren’t trying to do the same thing. Endoscopy can’t cure resectable cancer. Can the Whipple operation be done laparoscopically or robotically? Yes, in selected centres with surgeons trained in minimally invasive pancreatic surgery, with outcomes comparable to open Whipple in expert hands. Reference links- Pancreatic Adenocarcinoma Guidelines, National Comprehensive Cancer Network — https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455 Therapeutic Endoscopy in Pancreatic Disease, American Society for Gastrointestinal Endoscopy — https://www.asge.org/home/practice-support/guidelines

Borderline resectable pancreatic cancer (BRPC) is a stage where the tumour involves nearby blood vessels, making complete surgical removal (R0 resection) difficult or high-risk, though still technically possible. It lies between resectable and locally advanced disease, requiring multidisciplinary care, usually starting with neoadjuvant therapy (chemotherapy or radiation) to reduce tumour size. Around fifteen to twenty percent of pancreatic cancer diagnoses fall into this category, and accurate staging within the first few weeks decides whether conversion to resectable disease is realistic. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Borderline resectable is the category where the most damage gets done by rushing, patients pushed straight to surgery without neoadjuvant therapy often end up with positive margins or abandoned operations, and the ones given proper chemotherapy first frequently come back resectable a few months later with much better outcomes.” How borderline resectable disease is defined? It’s defined by the imaging, not by how the patient feels. A radiologist trained in pancreatic imaging looks at exactly how the tumour relates to four key vessels. Portal vein and superior mesenteric vein contact. Up to 180 degrees of contact, or short-segment occlusion that’s reconstructible, still keeps a case borderline rather than locally advanced. The vein is forgiving, surgeons can rebuild it if needed. Superior mesenteric artery involvement. Less than 180 degrees of contact is the threshold. Anything more than that pushes the case into locally advanced territory, where surgery isn’t appropriate anymore. The celiac axis and hepatic artery get measured the same way. Limited contact under 180 degrees keeps the case in borderline category, with the option of reconstruction during surgery if needed. Distant spread on imaging. Even small liver lesions or peritoneal deposits change the classification entirely. The cancer is no longer borderline, it’s metastatic, and the treatment route shifts to systemic chemotherapy. The classification isn’t a judgment call, it’s a measurement, and the measurement is what dictates the next step. Pancreatic cancer treatment planning at this point almost always starts with EUS-guided biopsy to confirm the histology before any chemotherapy begins, because the regimen choice depends on knowing exactly what the tumour is. How borderline cases are actually treated ? The standard approach now is chemotherapy first, surgery second, in patients who respond well enough to make resection worthwhile. The reasoning behind this shift has played out across multiple trials over the last decade. Neoadjuvant chemotherapy as the opening move. FOLFIRINOX is the most common regimen in fit patients, three to six months of it, followed by a restaging CT to see how the tumour has responded. Gemcitabine-based combinations are used in patients who can’t tolerate FOLFIRINOX. Restaging and decision-making. If the tumour has pulled back from the vessel and there’s no new disease elsewhere, surgery is on the table. If it hasn’t responded or has grown, the case is reclassified and the treatment plan changes entirely. Surgery, when it happens, is technically demanding. A Whipple procedure or distal pancreatectomy with possible vascular reconstruction, often three to four week recovery, and adjuvant chemotherapy afterwards is almost always recommended. What happens if conversion fails. Some borderline tumours don’t shrink, some grow despite chemotherapy, and these patients move into the locally advanced or metastatic category. Treatment then becomes about durable disease control rather than cure. The reason borderline resectable disease is its own category is because it behaves differently from both resectable and unresectable cancer. Read more on resectable vs unresectable pancreatic cancer to see how the staging logic separates these groups and why the treatment paths diverge so sharply. Why choose Dr. Vipulroy Rathod for borderline pancreatic cancer assessment? Dr. Vipulroy Rathod has been involved in the imaging review and EUS-based assessment of borderline pancreatic cancers at Fortis Hospital Mulund for over three decades. Many patients arrive having been told surgery is the next step, when a closer look at vessel involvement shows the case should have gone for neoadjuvant therapy first. The reverse also happens, patients told nothing can be done when the imaging actually puts them firmly in borderline territory with a real chance of conversion. The borderline category is where careful staging matters most. Push a patient into surgery too early and the operation gets abandoned. Wait too long without giving chemotherapy a real trial and the window closes. Both errors are avoidable with proper imaging review and EUS confirmation upfront. Book your consultation today with one of India’s most experienced specialists for borderline pancreatic cancer staging and treatment planning. Book Appointment Call now Frequently Asked Questions Can borderline resectable pancreatic cancer be cured? Yes, when the tumour responds well to neoadjuvant chemotherapy and successful surgery follows. Cure rates are lower than in fully resectable disease but meaningfully higher than in locally advanced cases, particularly when adjuvant chemotherapy is given afterwards. How long does chemotherapy last before surgery? Typically three to six months of FOLFIRINOX or a gemcitabine-based regimen, followed by a restaging scan. The exact duration depends on tolerance, response on imaging, and surgeon preference at the centre managing the case. What happens if borderline cancer doesn’t respond to chemotherapy? The case gets reclassified, usually as locally advanced. Surgery is taken off the table and treatment shifts to continued systemic therapy with or without radiation, focused on controlling the disease rather than removing it. Is borderline resectable pancreatic cancer the same as locally advanced? No. Borderline cases have limited vessel involvement that’s potentially reversible with chemotherapy, while locally advanced cases have arterial encasement that can’t be reconstructed even after good response. The distinction changes everything about prognosis and treatment options. Reference links- Pancreatic Adenocarcinoma Guidelines, National Comprehensive Cancer Network — https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455 Borderline Resectable Pancreatic Cancer Consensus, International Study Group of Pancreatic Surgery — https://www.surgjournal.com/article/S0039-6060(14)00227-5/fulltext

Resectable pancreatic cancer is the kind that can be surgically removed with a reasonable shot at cure. Unresectable means the tumour has grown into or wrapped around structures that no surgeon can safely take out. The line between the two is drawn on imaging, almost always a contrast-enhanced CT, and that line decides what the next year of treatment looks like. Only about one in five patients are resectable when they’re first diagnosed, which is partly why this disease still has such a bad reputation. A Gastroenterologist in Mumbai seeing these cases spends most of the first visit working out which category the patient falls into. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Patients are sometimes told their pancreatic cancer is operable when the imaging actually shows borderline involvement of a major vessel, and they end up in surgery that gets abandoned mid-procedure, which is the worst possible outcome and almost always preventable with proper staging upfront.” Resectable vs unresectable pancreatic cancer at a glance Factor Resectable Unresectable Vessel involvement No major contact Encases major artery Treatment intent Curative surgery Disease control only First-line approach Surgery upfront Chemotherapy first Five-year survival Twenty to thirty percent Under five percent Cases at diagnosis Fifteen to twenty percent Majority of patients   What separates resectable from unresectable disease ? It’s all about anatomy. Specifically, where the tumour sits in relation to the big vessels around the pancreas. Resectable. Tumour is in the pancreas, isn’t touching the superior mesenteric artery, celiac axis, or hepatic artery, and any contact with the portal or superior mesenteric vein is small enough to be reconstructed. Surgery here is being done with cure in mind. Borderline resectable. There’s some vessel contact, but not enough to rule surgery out. These cases almost always start with chemotherapy first, usually FOLFIRINOX or a gemcitabine combination, and the goal is to pull the tumour back from the vessel before anyone takes a scalpel to it. Locally advanced disease is a different conversation entirely. The artery is encased, the vessel can’t be reconstructed, and any surgeon attempting resection would do more harm than the cancer itself. Treatment becomes systemic chemotherapy with or without radiation. Metastatic. Once the cancer has reached the liver, the peritoneum, the lungs, or distant lymph nodes, surgery is off the table regardless of what the primary looks like. Chemotherapy now is about controlling progression and managing symptoms, not removing anything. The classification isn’t a footnote in the report, it’s the single decision that drives everything that follows. Pancreatic cancer treatment routes from this point on, whether neoadjuvant chemotherapy, surgery, or palliation, all rest on getting this initial reading right, which often means a second pair of trained eyes on the imaging and EUS for tissue confirmation. What changes between the two pathways ? Once the category is set, the treatment route diverges sharply. Patients should know what each path actually looks like before agreeing to it. Surgery upfront for resectable cases. A Whipple procedure for head-of-pancreas tumours, distal pancreatectomy for body and tail. Both are major operations and recovery is at least three to four weeks. Five-year survival sits between twenty and thirty percent with surgery alone, better when adjuvant chemotherapy is added. For borderline cases, chemotherapy comes first. Three to six months of FOLFIRINOX or a similar regimen, then a restaging scan to see what’s happened. If the tumour has pulled back, surgery becomes possible. If not, the chemo response itself tells you something about the biology. Definitive chemoradiation for locally advanced disease. No operation, but aggressive systemic and local treatment can shrink the cancer, ease symptoms, and occasionally bring a patient back into resectable territory. Most of the time the goal is durable disease control. Palliative care for metastatic disease. Chemotherapy to slow progression, biliary stenting if jaundice develops, EUS-guided celiac plexus block for pain, and frank conversations about prognosis from the first consultation onwards. Where a patient ends up depends entirely on how accurately the initial staging is done, which is why second opinions before any locked-in decision are common and reasonable. Read more on pancreatic cancer detection to understand why most of these cases are already past resectable by the time they’re picked up. Why choose Dr. Vipulroy Rathod for pancreatic cancer assessment? Dr. Vipulroy Rathod has been involved in staging and endoscopic assessment of pancreatic cancer at Fortis Hospital Mulund for over thirty years, with a particular focus on EUS-guided biopsy and the careful imaging review that decides resectability. Many of the patients we see arrive with a CT report calling their cancer operable, when a closer look at the vessel involvement tells a quite different story. Re-reading the scan properly often saves a patient from a surgery that was never going to succeed. The first few decisions in pancreatic cancer are the most consequential. Get the staging right and the rest of the plan follows logically. Get it wrong and the patient loses months on the wrong pathway, which in this disease is time nobody has. Book your consultation today with one of India’s most experienced specialists for pancreatic cancer staging and treatment planning. Book Appointment Call now Frequently Asked Questions How is resectability decided in pancreatic cancer? A contrast-enhanced CT looks at how the tumour sits in relation to the superior mesenteric artery, celiac axis, hepatic artery, and portal vein. There are specific criteria around degree of vessel contact that define each category, and the imaging is usually reviewed by both a radiologist and a surgical team before the final call is made. Can borderline resectable pancreatic cancer become resectable? Yes, and this happens often enough to be worth attempting. Neoadjuvant chemotherapy, sometimes paired with radiation, can shrink the tumour back from the involved vessel, and a restaging scan a few months later tells you whether resection is now safe. Is unresectable pancreatic cancer treatable? Treatable yes, curable usually not. Chemotherapy and radiation can control the disease for a meaningful period, manage symptoms, and extend survival. A small group of patients

Most pancreatic cysts are harmless, the trouble is that a small but real proportion aren’t, and telling them apart on imaging alone is one of the harder calls in GI medicine. Roughly one in fifteen cysts picked up incidentally on a scan has malignant potential, and another small group are already early cancers by the time they’re found. The type of cyst matters far more than the size, although both factor into the decision. Any Gastroenterologist in Mumbai who sees these regularly will tell you the worst mistake is assuming a cyst is benign without proper characterisation. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Patients are often told their pancreatic cyst is nothing to worry about because it’s small, but size alone is a poor predictor, mucinous cysts of two centimetres can still progress to cancer while serous cysts of seven centimetres almost never do, and the only way to know which one you’re dealing with is proper EUS evaluation with fluid analysis.” The pancreatic cyst types and their cancer risk Not all cysts behave the same way, and grouping them is what the entire workup hinges on. Serous cystadenoma. Almost always benign, the cancer risk is well under one percent. These are usually small, multi-loculated, and look like a honeycomb on imaging. Most can be watched and never need anything done. Mucinous cystic neoplasm, MCN. Found mostly in middle-aged women, in the body or tail of the pancreas. These do have malignant potential, around ten to fifteen percent harbour cancer at the time of surgery, and the consensus is that most should be resected once identified. Intraductal papillary mucinous neoplasm, IPMN. The most common cyst with cancer potential, and the most complicated to manage. Risk depends on subtype: main-duct IPMN carries a high risk of malignancy, around forty to seventy percent, while branch-duct IPMN sits at a much lower five to fifteen percent unless worrisome features develop. Solid pseudopapillary neoplasm. Rare, mostly in young women, low but real malignant potential. Usually treated with surgical resection because of the long lifespan ahead of the patient. Pseudocysts. Not true neoplasms, these form after pancreatitis and don’t turn cancerous. They can mimic cystic tumours on imaging though, which is why fluid analysis matters. The decision between watch-and-wait and surgical resection comes down to which type is sitting in front of you. Endoscopic ultrasound with fine-needle aspiration is the test that pulls fluid for cytology, CEA, glucose, and now molecular markers, all of which sharpen the diagnosis considerably beyond what a CT or MRI alone can say. Worrisome features that change the management Even within a cyst type, certain findings raise the concern level enough to move a case from surveillance into the operating theatre. Size above three centimetres in a branch-duct IPMN, especially with growth on follow-up scans. Steady growth is sometimes more concerning than the absolute number. A mural nodule or solid component inside the cyst on imaging. This is the single most worrying finding because it often correlates with high-grade dysplasia or invasive cancer. Main pancreatic duct dilation above five millimetres, particularly with cyst communication. This shifts the diagnosis towards main-duct or mixed IPMN, which carries the highest malignant risk. Jaundice, new-onset diabetes, or unexplained weight loss alongside the cyst. These are clinical red flags that the cyst may already be doing something it shouldn’t. Cyst fluid markers. High CEA suggests mucinous, low glucose suggests mucinous, and the newer KRAS and GNAS mutation testing has improved diagnostic accuracy significantly over the last few years. Worrisome features don’t always mean cancer, but they almost always mean the patient needs closer evaluation rather than a routine yearly scan. Read more on pancreatic cancer vs pancreatic cyst for how the distinction is drawn in cases where imaging alone leaves the question open. Why choose Dr. Vipulroy Rathod for pancreatic cyst assessment ? Dr. Vipulroy Rathod has been performing EUS-guided assessment of pancreatic cysts at Fortis Hospital Mulund since the late 1990s, which puts him among the earliest endosonographers in India to characterise these lesions properly. Many of the patients we see have been told their cyst is benign on the basis of a CT scan alone, which is exactly the kind of incomplete workup that misses the cases that needed earlier surgical referral. The judgment call on a pancreatic cyst sits between two errors. Over-treat a benign serous cystadenoma and the patient gets unnecessary surgery on a notoriously difficult organ. Under-treat a main-duct IPMN and the patient comes back two years later with pancreatic cancer. Volume and proper EUS technique are what keep both errors rare. Book your consultation today with one of India’s most experienced specialists for pancreatic cyst characterisation and surveillance planning. Book Appointment Call now Frequently Asked Questions Are all pancreatic cysts cancerous? No, most are benign. The ones with malignant potential are mainly mucinous cystic neoplasms and intraductal papillary mucinous neoplasms, and even within those groups not every cyst becomes cancer. How often should pancreatic cysts be monitored? Surveillance intervals depend on the type, size, and worrisome features. Small branch-duct IPMNs without concerning features are often watched every six to twelve months, while larger or more complex cysts may need imaging every three to six months. Can pancreatic cysts be removed without surgery? Surgical resection remains the standard for cysts with high cancer risk. Some experimental endoscopic ablation techniques exist for specific cyst types, but they aren’t yet routine and aren’t appropriate for cysts already showing worrisome features. Do pancreatic cysts cause symptoms? Most are silent and found incidentally on scans done for other reasons. Larger ones can cause abdominal pain, back pain, or jaundice if they press on nearby structures, and new-onset diabetes or weight loss in someone with a known cyst is always a warning sign. Reference links- Pancreatic Cyst Management Guidelines, American Gastroenterological Association — https://gastro.org/clinical-guidance/asymptomatic-neoplastic-pancreatic-cysts/ IPMN and Mucinous Cyst Consensus Recommendations, International Association of Pancreatology — https://pancreapedia.org/reviews/international-consensus-fukuoka-guidelines-for-management-of-ipmn-and-mcn-of-pancreas

Walled-off pancreatic necrosis, or WON, is what dead pancreatic tissue becomes once the body has had four to six weeks to build a thick capsule around it. Before that wall forms, the dead area is loose, soft, and unsafe to touch. After the wall forms, it can be drained, accessed, and eventually cleared out without open surgery. Most patients reach this stage after a severe episode of acute pancreatitis with necrosis, and timing matters more here than in almost any other GI condition a Gastroenterologist in Mumbai deals with. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “WON is one of the few situations in gastroenterology where waiting is the right thing to do, the cavity has to mature before drainage is safe, and patients who get rushed into procedures during the first three weeks usually end up worse than the ones who were watched carefully and treated at the right time.” How walled-off necrosis forms and how it gets diagnosed? The wall doesn’t appear overnight, it’s the body doing slow inflammatory work, and recognising the stage on imaging is what tells the treating doctor whether to act or to keep waiting. The dying phase, week one to two. Severe acute pancreatitis kills off sections of the pancreas and the fat surrounding it. At this stage there’s no capsule, just necrotic tissue mixed with fluid sitting in the upper abdomen. Inflammation and demarcation, week three to four. The body starts forming a fibrous reaction around the dead area. The contents stay messy, partly solid, partly liquid, but a boundary begins to appear on CT. Walled-off stage, after week four. A thick non-epithelial wall now contains the necrosis. This is the point at which the lesion gets formally called WON, and it’s the point at which endoscopic drainage actually becomes a reasonable option. Imaging confirmation. Contrast-enhanced CT or MRI is the test of choice, both to confirm wall maturity and to see whether infection, gas bubbles, or new fluid pockets have developed alongside. Reading the imaging right is half the management. Once a mature wall is confirmed and the patient has symptoms, pancreatic stone extraction and EUS-guided cavity drainage can be planned safely, often as the same procedure if the anatomy allows How walled-off necrosis is treated, step by step? Not every WON needs intervention. Some shrink on their own once the wall has matured fully, the body absorbs the contents over months, and the patient never needs a procedure. The ones that do need treatment usually announce themselves through symptoms or infection. Watch and wait when the patient is well, the cavity is small, and there’s no infection. Repeat scans every few weeks, monitor for fever or weight loss, intervene only if something changes. EUS-guided drainage for symptomatic or infected collections. A stent, often a lumen-apposing metal stent, is placed through the stomach or duodenum directly into the cavity under ultrasound guidance. Fluid drains out, the cavity starts to collapse. Direct endoscopic necrosectomy. Once a stent is in place, the same opening can be used in follow-up sessions to enter the cavity with a scope and physically remove dead tissue. This is repeated, sometimes five or six times, until the cavity is clean. Stent removal and follow-up. When the cavity has shrunk and there’s no more debris, the stent comes out. Imaging at three and six months confirms the cavity has closed. The hardest part for patients is accepting that treatment isn’t one event, it’s a sequence. Read more on pancreatic necrosis treatment for how the step-up approach plays out across multiple sessions in real cases. Why choose Dr. Vipulroy Rathod for walled-off necrosis management ? Dr. Vipulroy Rathod has been managing walled-off necrosis at Fortis Hospital Mulund for over three decades, including some of the earliest EUS-guided drainage cases performed in India. Many of the patients we see arrive after weeks of antibiotics elsewhere, with collections that should have been drained sooner or, occasionally, ones that were touched too early and made worse. Getting WON right is mostly about timing and access. The procedure itself is technically demanding, but the bigger judgment call is choosing the right week to intervene and the right route into the cavity. Both come with volume. Book your consultation today with one of India’s most experienced specialists for walled-off pancreatic necrosis assessment and endoscopic drainage. Book Appointment Call now Frequently Asked Questions How long does walled-off pancreatic necrosis take to form? A mature wall usually takes four to six weeks after the original episode of acute pancreatitis. Before this window, the collection is called acute necrotic collection, not WON, and it isn’t safe to drain. Can walled-off necrosis resolve on its own? Smaller, sterile, asymptomatic collections often shrink and get absorbed over several months without any intervention. Larger ones, infected ones, or any that cause pain, fever, or pressure on nearby organs do need drainage. Is endoscopic drainage of WON painful? The procedure is done under sedation or general anaesthesia and patients don’t feel it. There can be some abdominal discomfort for a day or two afterwards, but most patients are eating and moving within twenty-four hours. What happens if walled-off necrosis is left untreated? If it stays sterile and small, sometimes nothing. If it gets infected or grows large, it can cause sepsis, compress the bile duct or stomach outlet, bleed, or perforate. These complications are why most symptomatic cases need active management. Reference links- Acute Pancreatitis Management Guidelines, American College of Gastroenterology — https://gi.org/guideline/acute-pancreatitis/ Necrotising Pancreatitis Treatment Standards, World Gastroenterology Organisation — https://www.worldgastroenterology.org/guidelines/acute-pancreatitis/acute-pancreatitis-english

Pancreatic necrosis means part of the pancreas has died, usually after a severe attack of acute pancreatitis cuts off its own blood supply. It happens in roughly one out of every five or six severe cases, and once tissue is gone, it’s gone, the pancreas can’t grow it back. The bigger problem isn’t the dead tissue itself, it’s what happens when bacteria find their way into it. A Gastroenterologist in Mumbai who handles severe pancreatitis spends most of the effort stopping that infection from setting in. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Most patients with pancreatic necrosis we see in 2026 are managed endoscopically rather than surgically, which is a complete reversal of how this condition was treated even 15 years ago when open necrosectomy was the default and mortality sat above 30 percent.” How pancreatic necrosis develops and what it looks like? Necrosis builds in stages, and the stage you catch it at decides what kind of treatment is even possible. Inflammation first. Severe acute pancreatitis sets enzymes loose inside the pancreas itself, the small vessels feeding it get damaged, and within three or four days, certain pockets of the organ stop getting blood. That’s where the dying starts. Tissue death. With perfusion gone, sections of the pancreas and the fat around it turn necrotic. Soft, unencapsulated, no clear border. You can’t see this clinically, only a contrast CT or MRI tells you how much has been lost. The wall forms. Over the next four to six weeks the body does something useful, it builds a thick capsule around the dead tissue. This is walled-off necrosis, or WON, and it’s the stage at which endoscopic drainage becomes safe to attempt. Infection. About thirty percent of cases get infected when gut bacteria translocate into the dead collection. Fever, rising white counts, deterioration. This is the version that kills people, and confirming it usually means a fine-needle aspiration or a clinical picture that makes the diagnosis obvious. Where the patient sits in that sequence matters more than the necrosis itself. Caught during the walled-off phase, the collection is often manageable with endoscopic drainage rather than the open surgical debridement that used to be routine. How pancreatic necrosis is treated without open surgery? The way this disease is treated has shifted more in the last ten years than in the four decades before it, and the shift has saved a lot of lives. Step-up, not all-at-once. Start with whatever is least invasive, escalate only when the previous step fails. Open surgery is now the last resort, not the default, because the mortality difference is large enough that nobody serious recommends going straight to it anymore. EUS-guided stent drainage. A stent placed through the stomach wall straight into the necrotic cavity under ultrasound guidance. It drains pus and fluid continuously, gives the dead material a route out, and lets the cavity slowly shrink. Endoscopic necrosectomy. Once drainage is established, the same access point can be used to go in with a scope and remove dead tissue physically, in repeated sessions, over weeks. It’s not one big procedure, it’s a sequence of smaller ones. Percutaneous drainage when endoscopic access doesn’t work, usually because of where the collection sits anatomically. A catheter goes in through the skin, and if drainage alone isn’t enough, the same tract can be used for minimally invasive debridement later. Centres doing this at volume have brought mortality in necrotising pancreatitis from above thirty percent down to under ten. Read more on pancreatic necrosis treatment for how the step-up approach actually unfolds case by case. Why choose Dr. Vipulroy Rathod for pancreatic necrosis management ? Dr. Vipulroy Rathod has been managing necrotising pancreatitis at Fortis Hospital Mulund for over three decades. Many of the patients we see have already been through weeks of antibiotics elsewhere before anyone offered drainage, and by then the cavity is fully walled off and the patient is exhausted. The endoscopic route still works at that point, but timing it correctly, choosing the right access, and knowing when to escalate are all judgment calls that volume teaches. Necrosis isn’t a condition that should be managed in centres that see one or two cases a year. It needs a team that does this routinely, with the imaging, the scopes, and the experience to know when to drain and when to wait. Book your consultation today with one of India’s most experienced specialists for pancreatic necrosis assessment and minimally invasive drainage. Book Appointment Call now Frequently Asked Questions Is pancreatic necrosis fatal? It can be, particularly once the dead tissue gets infected. In centres doing endoscopic management at volume, mortality is under ten percent, but it climbs sharply when infected necrosis is recognised late or pushed straight to open surgery. Can the pancreas recover after necrosis? The organ keeps working with whatever tissue survived, but the dead portion doesn’t regenerate. Depending on how much functional pancreas was lost, patients may end up needing enzyme replacement, may develop diabetes, or sometimes both. How long does pancreatic necrosis take to heal? Walling-off itself takes four to six weeks. After that, endoscopic drainage and necrosectomy sessions usually span another six to twelve weeks before the cavity closes properly. It’s a slow disease to manage and patients should be told that upfront. What is the difference between pancreatic necrosis and pseudocyst? A pseudocyst is fluid only. Necrosis contains solid dead tissue along with fluid, which is why it can’t be managed by drainage alone, the solid material has to be physically removed in stages. Reference links- Acute Pancreatitis Management Guidelines, American College of Gastroenterology — https://gi.org/guideline/acute-pancreatitis/ Necrotising Pancreatitis Treatment Standards, World Gastroenterology Organisation — https://www.worldgastroenterology.org/guidelines/acute-pancreatitis/acute-pancreatitis-english

Yes and in most patients who end up with chronic disease, it already has before they ever see someone like me. One mild acute episode, the pancreas usually bounces back, heals up, no lasting problem. But keep having episodes, or have one bad one with necrosis, and the organ starts losing tissue it can’t replace. Scar where enzymes used to be made. Scar where insulin used to be produced. That doesn’t reverse when you stop drinking or fix whatever caused it, because fibrosis has its own momentum once it starts. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “The question isn’t whether pancreatitis can cause permanent damage, it’s whether the damage has already happened by the time the patient arrives, because most chronic pancreatitis patients we see have been symptomatic for years before anyone staged the extent of what’s been lost.” What Kind of Permanent Damage Does Pancreatitis Cause? Two jobs. Digestion and blood sugar. Chronic pancreatitis can permanently wreck both, and most patients don’t find out until both are already significantly impaired. Exocrine: Enzyme-producing cells replaced with scar over repeated episodes, and once 90% of that capacity is gone the patient develops oily stools, malabsorption, weight dropping despite eating normally, vitamin deficiencies nobody explained, and needs lifelong enzyme replacement because those cells aren’t regenerating no matter how long you wait or how clean the diet gets. Endocrine: Islet cells producing insulin sit in the same tissue getting damaged, get destroyed alongside the acinar cells, nobody monitors the loss until diabetes shows up, and the diabetes you get from pancreatitis is genuinely harder to manage than standard Type 2 because both insulin and glucagon responses are impaired at the same time which makes blood sugar swing unpredictably. Ductal: Scar narrows the main duct, calcifications form, stones develop, enzyme drainage drops, pressure builds behind the blockage, patient gets pain that no painkiller on earth will fix because what’s causing it is a physical obstruction not inflammation and the only thing that helps is opening the duct endoscopically or surgically. Structural: Pseudocysts, walled-off necrosis, splenic vein thrombosis, bile duct compression from pancreatic head fibrosis, these are permanent architectural changes that don’t resolve on their own and each one alters how the patient needs to be managed going forward in ways that generic pancreatitis treatment doesn’t account for. Knowing how much damage has accumulated changes what management actually looks like. Specialist in pancreatitis treatment stages through fecal elastase, EUS, and functional assessment rather than treating symptoms blind without knowing what’s left to work with. Can Permanent Pancreatic Damage Be Prevented or Slowed? Some of it, yes, if the cause gets addressed early. But the window closes faster than patients think, and faster than most doctors communicate. Cause: Remove the trigger early, that’s the single most effective thing. Alcohol cessation for alcohol-related disease, cholecystectomy after gallstone pancreatitis, genetic counselling for hereditary cases, and every episode that happens after the cause could have been addressed is damage that didn’t need to happen, scar tissue added to a pancreas already running out of functional reserve. Episodes: Each attack adds damage incrementally and the gap between recurrent acute pancreatitis and established chronic disease is shorter than anyone tells patients, which is why preventing recurrence matters more than treating each episode after it’s already happened and hoping the pancreas holds up through the next one. Monitoring: Fecal elastase for enzyme output, HbA1c for insulin function, EUS for structural assessment, regular follow-up to catch complications before they announce themselves through a hospital admission, all of this on a schedule rather than reactively after something goes wrong because by the time symptoms force the conversation the damage has usually progressed another step. PERT: Enzyme replacement at the right dose prevents the malnutrition and vitamin deficiencies that pile on top of the pancreatic damage itself, and most patients we put on PERT wish someone had tested their function and started replacement years earlier rather than managing symptoms as IBS while the malabsorption quietly got worse underneath. How much permanent damage accumulates depends on how early the cause is addressed and how closely someone is watching between episodes. Read more on gallstone pancreatitis to understand how one of the most common and preventable causes is managed and why removing the source after the first episode prevents the kind of repeat damage that eventually becomes irreversible. Why Choose Dr. Vipulroy Rathod for Pancreatitis-Related Permanent Damage? Dr. Vipulroy Rathod has spent over 30 years assessing pancreatic damage at Fortis Hospital Mulund. Patients whose chronic pancreatitis had been managed symptomatically for years without anyone measuring what was left. Duct strictures opened through ERCP. Enzyme replacement started at proper doses in patients malnourished for years without a diagnosis. 35 countries worth of physicians trained in this functional assessment approach. Patients arrive knowing they have chronic pancreatitis but not knowing what that actually means for their digestion, their diabetes risk, or how they’re going to feel next year. Most leave understanding where their pancreas stands and what the plan is for protecting whatever function hasn’t been lost yet.   Book your consultation today with one of India’s most experienced specialists for chronic pancreatitis assessment and permanent damage management. Book Appointment Call now Frequently Asked Questions Does one episode of pancreatitis cause permanent damage? A single mild acute episode usually resolves without lasting damage, but severe acute pancreatitis with necrosis can cause permanent tissue loss even from one episode. How do you know if pancreatitis has caused permanent damage? Fecal elastase testing, HbA1c monitoring, and EUS or imaging assessment together show how much exocrine and endocrine function has been lost. Can permanent pancreatic damage be reversed? Fibrotic scar tissue replacing functional pancreatic cells is permanent and cannot be reversed, but progression can be slowed by removing the underlying cause and managing complications. Does chronic pancreatitis always lead to diabetes? Not always, but a significant proportion of chronic pancreatitis patients develop pancreatogenic diabetes as insulin-producing islet cells are destroyed by progressive inflammation. Reference links- Chronic Pancreatitis and Permanent

Gallstone pancreatitis happens when a small stone slips out of the gallbladder, travels down the common bile duct, and gets stuck at the ampulla where the bile and pancreatic ducts share an opening. Enzymes back up, the pancreas inflames, and the patient gets sudden severe upper abdominal pain that radiates to the back along with nausea, vomiting, and blood work showing elevated amylase and lipase. It’s the second most common cause of acute pancreatitis in India after alcohol, and the frustrating part is that most recurrent cases could have been prevented if someone had removed the gallbladder after the first episode. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Gallstone pancreatitis is one of the most preventable causes of recurrent pancreatitis because removing the gallbladder after the first episode stops the problem at its source, yet a surprising number of patients leave hospital after the acute episode without anyone scheduling the cholecystectomy that would prevent the next one.” What Causes Gallstone Pancreatitis and How Is It Diagnosed? One stone in the wrong place. That’s the entire mechanism, but the consequences can be severe if it isn’t dealt with quickly. Mechanism: Small gallstone migrates into the cystic duct, travels down the common bile duct, lodges at the ampulla of Vater, blocks pancreatic enzyme drainage completely, enzymes activate inside the organ, and the pancreas starts digesting itself because of one stone that might be 5mm across sitting in exactly the wrong spot. Who: Women more than men, patients with multiple small gallstones rather than one large one because small stones are the ones that migrate, obesity, rapid weight loss, pregnancy all increase formation, and the patient who had biliary colic last year and was told to watch and wait is exactly the one who shows up with gallstone pancreatitis this year wondering why nobody took the gallbladder out when they had the chance. Diagnosis: Elevated amylase, lipase, bilirubin, liver enzymes on blood work, ultrasound confirms gallstones and sometimes shows dilated bile duct, but the stone that caused the pancreatitis may have already passed by the time anyone scans, so a normal-looking bile duct doesn’t rule it out when the bloods and the clinical picture fit together. Severity: Most cases are mild and self-limiting, patient improves within 3 to 5 days with supportive care, but about 20% develop severe disease with organ failure, necrosis, or infected collections that turn a week-long admission into a month in ICU, and mild versus severe gallstone pancreatitis are essentially different diseases wearing the same name. Confirming the cause early changes the treatment timeline completely. Specialist in pancreatitis treatment differentiates gallstone pancreatitis from other causes quickly because the treatment pathway is fundamentally different from alcohol-related or idiopathic cases. How Is Gallstone Pancreatitis Treated? Two problems need solving in the same admission and missing the second one is how patients end up back in hospital months later with the same preventable episode. ERCP: If the stone is still impacted at the ampulla, ERCP removes it endoscopically within 24 to 72 hours, scope through the mouth, sphincterotomy at the ampulla, stone pulled out with balloon or basket, and pain relief is often dramatic because the obstruction causing the enzyme backup has been physically removed in the same session that diagnosed the impaction. Supportive: IV fluids, pain control, fasting until the pancreas settles, most patients improve within days, and early feeding once pain allows is current practice rather than the prolonged fasting that was standard a decade ago because we now know keeping the gut active supports recovery rather than delaying it. Cholecystectomy: Gallbladder needs removing after the acute episode resolves, during the same admission for mild cases, after 4 to 6 weeks for severe cases, and this is the step that prevents recurrence, the step that gets missed most often, the step where the patient feels better, goes home, nobody schedules the surgery, and 6 months later they’re back with another episode that was entirely preventable because the source was still sitting there producing stones. Complications: Severe cases with necrosis or infected collections need ICU management sometimes for weeks, walled-off necrosis may need EUS-guided transmural drainage or direct endoscopic necrosectomy weeks later, and these are the cases that start as gallstone pancreatitis and end up as complex pancreatic disease requiring months of management that nobody anticipated when the patient first presented with what looked like a straightforward acute episode. The acute episode is treatable and preventing the next one requires removing the source. Read more on alcohol and pancreatitis to understand how the other major pancreatitis cause differs in mechanism, damage pattern, and what long-term management actually looks like. Why Choose Dr. Vipulroy Rathod for Gallstone Pancreatitis? Dr. Vipulroy Rathod has spent over 30 years managing gallstone pancreatitis at Fortis Hospital Mulund, from urgent ERCP stone extraction in the acute phase through EUS-guided drainage of complicated collections weeks later. Stones removed endoscopically that would have needed open surgery at centres without ERCP capability. Necrosis managed through the scope without surgical debridement. 35 countries worth of physicians trained in this approach. Patients arrive in acute pain with a stone lodged at the ampulla and most leave with the stone out, the duct clear, and a cholecystectomy scheduled so the whole thing doesn’t happen again.   Book your consultation today with one of India’s most experienced specialists for gallstone pancreatitis treatment and ERCP. Book Appointment Call now Frequently Asked Questions What causes gallstone pancreatitis? A gallstone migrating from the gallbladder and blocking the ampulla where the bile and pancreatic ducts meet causes acute pancreatic inflammation. How is a gallstone removed during pancreatitis? ERCP accesses the ampulla endoscopically, performs sphincterotomy, and extracts the impacted stone using a balloon or basket without surgical incision. Can gallstone pancreatitis happen again after treatment? Yes, without cholecystectomy the recurrence risk is 30 to 50% within weeks to months, making gallbladder removal essential after the acute episode resolves. How serious is gallstone pancreatitis? Most cases are mild and resolve within days, but about 20% develop severe disease

Alcohol has no universally safe threshold as most data points validate 4 to 5 drinks per day for 5 or more years as the range where chronic pancreatitis risk climbs significantly, but some patients develop it with less and others drink heavily for decades without pancreatic damage. Genetics, smoking, diet, and individual susceptibility all modify the risk. What we do know for certain is that alcohol causes roughly 40 to 70% of chronic pancreatitis cases in India, and by the time patients come to us with established disease most have been drinking at levels they considered moderate for years without anyone flagging the pancreatic risk specifically. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Patients always ask how much alcohol is safe for the pancreas and the honest answer is that we cannot give a number that guarantees safety, because individual susceptibility varies enormously and some patients develop severe chronic pancreatitis at drinking levels their friends handle without any pancreatic consequences.” How Does Alcohol Damage the Pancreas? Not one mechanism. Several running simultaneously. And the damage accumulates quietly for years before anything shows up clinically. Toxic Metabolites: Alcohol breaks down into acetaldehyde and fatty acid ethyl esters inside the pancreas, both directly toxic to acinar cells. The damage from each drinking session is small on its own. The problem is cumulative. Years of repeated low-grade toxic exposure eventually crosses the threshold into clinical disease, and there’s no blood test that tells you when you’ve reached that point. Premature Enzyme Activation: Alcohol disrupts the mechanisms that keep digestive enzymes inactive inside the pancreas. Trypsinogen activates into trypsin prematurely. The pancreas starts digesting itself. One episode of this is acute pancreatitis. Repeated episodes from continued drinking is how chronic pancreatitis develops, and each episode adds scar tissue that doesn’t reverse when the patient stops drinking. Ductal Changes: Alcohol causes protein plugs to form inside the pancreatic ducts, these calcify over time into stones, ducts narrow, enzyme drainage drops, pressure builds behind the obstruction, and the patient develops the constant pain of chronic pancreatitis that medication doesn’t touch because the problem is structural not inflammatory anymore. Stellate Cell Activation: Alcohol activates pancreatic stellate cells that produce collagen and fibrotic tissue. Once activated, these cells keep producing scar tissue even after the patient stops drinking. That’s the part most patients don’t understand. The fibrosis process has its own momentum. Stopping alcohol slows it considerably but doesn’t always stop it completely in advanced disease. The damage is real and cumulative. Specialist in pancreatitis treatment assesses where on the damage spectrum a patient sits rather than just telling them to stop drinking and hoping the pancreas sorts itself out. How Much Alcohol Actually Causes Pancreatitis? No clean cutoff exists. But the data gives ranges that are worth knowing honestly. Quantity: Most studies show significantly elevated chronic pancreatitis risk at 4 to 5 or more drinks daily sustained over 5 years. But some patients develop disease at 2 to 3 drinks daily. And some heavy drinkers never get pancreatitis at all. The variation is real. It’s genetic. And it means nobody can tell you your specific safe limit because your pancreas doesn’t come with a manual. Duration: Duration matters as much as quantity. Ten years of moderate drinking may cause more damage than two years of heavy drinking depending on the individual, because the cumulative toxic exposure is what drives fibrosis and once stellate cells activate the process self-sustains to some degree. Smoking: Smoking alongside alcohol multiplies pancreatic damage significantly. The two don’t just add risk. They compound it. Smokers develop alcohol-related pancreatitis earlier, progress to chronic disease faster, and have higher rates of pancreatic cancer on top of that. Patients who drink and smoke are in a genuinely different risk category from those who only drink. Genetics: SPINK1 and CFTR mutations lower the threshold for alcohol-related pancreatic damage significantly. Patient with a SPINK1 variant who drinks moderately may develop pancreatitis at levels that wouldn’t affect someone without the mutation. This is why genetic testing matters in young patients with alcohol-related pancreatitis, because the alcohol might be the trigger but the genetics are the reason it happened at that level of exposure. There’s no magic number. But there are patterns worth knowing. Read more on hereditary pancreatitis to understand how genetic factors interact with alcohol exposure to produce pancreatitis at levels most people wouldn’t consider dangerous. Why Choose Dr. Vipulroy Rathod for Alcohol-Related Pancreatitis? Dr. Vipulroy Rathod has spent over 30 years managing alcohol-related pancreatitis at Fortis Hospital Mulund. Patients presenting with first episodes who needed genetic testing that revealed underlying susceptibility nobody expected. Chronic pancreatitis managed through ERCP stenting and EUS-guided intervention that kept patients out of surgery. Honest conversations about drinking thresholds that don’t exist on paper but matter clinically. 35 countries worth of physicians trained in this approach. Patients arrive having been told to stop drinking without being told what damage has already occurred or what the pancreas actually looks like now. Most leave with a proper assessment of where they sit, what’s reversible, what isn’t, and a management plan built around their specific disease stage rather than generic advice.   Book your consultation today with one of India’s most experienced specialists for alcohol-related pancreatitis assessment and management. Book Appointment Call now Frequently Asked Questions How much alcohol causes pancreatitis? Most studies show significantly elevated risk at 4 to 5 drinks daily over 5 years, but individual susceptibility varies and some patients develop disease at lower levels. Can the pancreas recover after stopping alcohol? Early damage can partially recover with complete alcohol cessation, but established chronic pancreatitis with fibrosis is usually permanent and requires ongoing management. Does the type of alcohol matter for pancreatitis risk? Total alcohol content matters more than the type of drink, so beer, wine, and spirits all carry risk proportional to the amount of ethanol consumed. Why do some heavy drinkers never get pancreatitis? Genetic variations in SPINK1, CFTR, and other genes determine individual susceptibility, meaning some people tolerate

Hereditary pancreatitis is a genetic condition where mutations in specific genes cause the pancreas to inflame repeatedly, usually starting in childhood or adolescence, without the typical triggers like alcohol or gallstones. PRSS1 gene mutation is behind most cases. The trypsinogen produced by the mutated gene activates prematurely inside the pancreas and starts digesting the organ from within. Episodes keep recurring throughout life, chronic pancreatitis develops by early adulthood in most patients, and lifetime pancreatic cancer risk climbs to 40 to 55% by age 70, a number most families carrying this mutation have never been told. According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Hereditary pancreatitis is one of those conditions where the diagnosis changes the management for the entire family, not just the patient in front of you, because siblings and children need genetic testing and surveillance that nobody will offer them unless someone connects the first case to its genetic origin.” What Causes Hereditary Pancreatitis and How Is It Diagnosed? Alcohol is behind most cases. But the diagnosis is tricky because everything about it looks like cancer until you prove otherwise. Alcohol: Chronic heavy drinking is the primary driver in most cases we diagnose. The inflammation concentrates specifically in the groove between the pancreatic head and the duodenum rather than affecting the whole organ, and that focal pattern is exactly what makes it look like a mass on imaging rather than diffuse pancreatitis that’s easier to recognise. Mechanism: Repeated alcohol-induced inflammation damages the minor papilla area, causes protein plugs and cystic changes in the duodenal wall, fibrosis develops in the groove, and over time the whole area thickens into what looks like a solid mass on CT. The duodenal wall itself gets involved. That’s unusual for standard pancreatitis and it’s one of the features that distinguishes groove pancreatitis from other forms. Mimics Cancer: CT and MRI show a mass in the pancreatic head region with duodenal wall thickening, bile duct narrowing, and sometimes cystic changes. Looks like cancer. Radiologist reports it as suspicious. Surgeon gets consulted. Patient is terrified. And in a proportion of cases, the whole thing turns out to be inflammatory. The problem is that nobody can be 100% certain without tissue, and that’s where EUS comes in. Diagnosis: EUS gets close enough to see the groove in detail that external imaging can’t match, characterises the tissue pattern, identifies the cystic changes within the duodenal wall that are more typical of groove pancreatitis than cancer, and provides FNA biopsy of the thickened area. Biopsy showing fibrosis and inflammation without malignant cells is what finally settles the question for most patients. Getting this diagnosis right avoids unnecessary surgery. Specialist in endoscopic ultrasound differentiates groove pancreatitis from pancreatic cancer using tissue-level detail that CT and MRI can suggest but never confirm. How Is Hereditary Pancreatitis Managed and Why Does Cancer Surveillance Matter? Management is lifelong. And the cancer risk that comes with this diagnosis is the part most patients aren’t told about early enough. Episodes: Acute attacks managed the same way as any pancreatitis episode, IV fluids, pain control, fasting, supportive care. The difference is these attacks keep coming back. Every few months. Every year. And each episode adds more damage to the pancreas, pushing the patient closer to chronic disease and exocrine insufficiency with every round. Chronic: Most patients develop chronic pancreatitis by their 20s or 30s. Pain becomes persistent. Enzyme deficiency develops. Diabetes follows when enough endocrine tissue is destroyed. PERT for enzyme replacement, pain management through endoscopic or medical approaches, and lifestyle modification become the ongoing management plan for the rest of the patient’s life. Cancer: This is the part that keeps me up at night clinically. Lifetime pancreatic cancer risk in hereditary pancreatitis is 40 to 55% by age 70. Compare that to 1 to 2% in the general population. These patients need annual EUS surveillance starting at age 40, or 20 years after symptom onset, whichever comes first. Most of them are not on surveillance because nobody connected their pancreatitis to a genetic cause. Family: Autosomal dominant for PRSS1 means 50% chance each child inherits the mutation. Siblings, parents, and children of confirmed cases need genetic testing. Positive family members need their own surveillance plan. The diagnosis doesn’t stop at the patient. It extends to every first-degree relative who might be carrying the same mutation without knowing. Hereditary pancreatitis management is a lifelong commitment and the cancer surveillance piece is non-negotiable. Read more on cancer risk factors to understand how hereditary pancreatitis fits into the broader pancreatic cancer risk picture and why genetic predisposition changes the surveillance conversation completely. Why Choose Dr. Vipulroy Rathod for Hereditary Pancreatitis? Dr. Vipulroy Rathod has spent over 30 years managing pancreatic disease at Fortis Hospital Mulund, including hereditary pancreatitis cases where the genetic diagnosis had been missed for years while patients cycled through repeated episodes labelled as idiopathic. EUS surveillance programmes built for genetically confirmed patients. Family members tested and placed on their own monitoring schedules. 35 countries worth of physicians trained in this genetic-to-clinical approach. Patients arrive having been told they have unexplained pancreatitis. Most leave knowing exactly which gene mutation is driving it, what the cancer risk actually means for them, and what surveillance looks like for the rest of their life and their family’s.   Book your consultation today with one of India’s most experienced specialists for hereditary pancreatitis diagnosis, management, and cancer surveillance. Book Appointment Call now Frequently Asked Questions What gene causes hereditary pancreatitis? PRSS1 gene mutation is the most common cause of hereditary pancreatitis, producing trypsinogen that activates prematurely inside the pancreas. At what age does hereditary pancreatitis start? Most patients experience their first pancreatitis episode before age 20, with some cases presenting in childhood before age 10. Does hereditary pancreatitis increase cancer risk? Yes, lifetime pancreatic cancer risk reaches 40 to 55% by age 70 in hereditary pancreatitis patients, requiring annual EUS surveillance. Should family members be tested for hereditary pancreatitis? Yes, PRSS1 mutation is autosomal dominant with 50% inheritance